That means that, while there is now some evidence that J&J is protective against the delta variant, its overall efficacy is still lower than that of Pfizer-BioNTech or Moderna, said, a professor of microbiology and immunology at the Weill Cornell Medical College in New York.
in the United Kingdom shows that following a single dose of the Oxford-AstraZeneca shot with a Pfizer-BioNTech shot offered an immunity boost. “If and when FDA and CDC approve a change in policy, then it looks to me entirely appropriate to consider using the mRNAs as a boost for J&J,” said Moore. “Now that we have data that is encouraging that the vaccine might be protective against delta and that the duration of protection is a thing, those two together are encouraging that a booster might not be needed,” said Diemert., chair of the Department of Medicine at the University of California-San Francisco, said he doesn’t think an mRNA booster is necessary either — but he would still caution those who got J&J to be a bit more careful than those who received Pfizer-BioNTech or Moderna.
“These results are great news. I don’t find them surprising, but they are some of the data that was missing when I decided to take an mRNA booster,” said, a clinical pharmacy specialist in infectious diseases at Temple University Hospital in Philadelphia.
Philippines Latest News, Philippines Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.